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Abstract 
Objectives: To evaluate a novel method, named Colistin-MAC test, for phenotypic screening of 
acquired colistin-resistance mediated by transferable mcr-1 resistance determinants, based on 
colistin MIC reduction in the presence of dipicolinic acid (DPA).  
Methods: The Colistin-MAC test consists in a broth microdilution method, in which colistin MIC is 
tested in absence or presence of DPA (900 µg/mL). Overall, 74 colistin-resistant strains of 
Enterobacteriaceae (65 Escherichia coli and 9 of other species), including 61 strains carrying mcr-
1-like genes and 13 strains negative for mcr genes, were evaluated with the Colistin-MAC test. 
The presence of mcr-1-like and mcr-2-like genes was assessed by Real-Time-PCR and end-point 
PCR. For 20 strains, Whole-Genome Sequencing data were also available. 
Results: A ≥8-fold reduction of colistin MIC in the presence of DPA was observed with 59 mcr-1-
positive strains, including 53 E. coli of clinical origin, three E. coli transconjugants carrying MCR-
1-encoding plasmids, one Enterobacter cloacae complex, and two Citrobacter spp. Colistin MICs 
were unchanged, increased, or at most reduced by two-fold with the 13 mcr-negative colistin-
resistant strains (nine E. coli and four Klebsiella pneumoniae), but also with two mcr-1-like-positive 
K. pneumoniae strains.  
Conclusions: The Colistin-MAC test could be a simple phenotypic test for presumptive 
identification of mcr-1-positive strains among isolates of colistin-resistant E. coli, based on a ≥8-
fold reduction of colistin MIC in the presence of DPA. Evaluation of the test with a larger number 
of strains, species, and mcr-type resistance determinants would be of interest.  
 
 
Keywords: DPA-colistin synergy, phenotypic screening, colistin resistance, mcr-1, Colistin-MAC 
test 
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Introduction 
Polymyxins have lately regained a key role as last-resort antibiotics for treatment of infections 
caused by multidrug-resistant and extremely drug-resistant Gram-negative pathogens [1]. 
In Enterobacteriaceae, acquired resistance to polymyxins is mostly mediated by modification of the 
Lipid A target (by addition of 4-amino-4-deoxy-l-arabinose and/or phosphoethanolamine residues) 
that impair polymyxin binding [2]. Target modification can be dependent on chromosomal 
mutations upregulating the endogenous lipopolysaccharide modification systems, or by exogenous 
phosphoethanolamine transferases encoded by acquired mobilized colistin resistance (mcr) genes. 
Discovery of the latter mechanisms has raised considerable concern in view of their potential for 
spreading among clinical pathogens [3]. Indeed, after the first description [4], mcr-1 and variants 
thereof have been detected worldwide [5], while additional types of mcr genes (e. g. mcr-2, mcr-3 
and mcr-4) have recently been identified [6-8].  
Since MCR-1 is a zinc enzyme [9], exposure to chelators could reduce colistin resistance in MCR-
1-producing strains. Indeed, EDTA was recently reported to potentiate the activity of colistin 
against MCR-1-producing strains [9]. 
Here we describe a novel test (named Colistin-MAC test), based on colistin MIC reduction in the 
presence of dipicolinic acid (DPA), that could be useful for phenotypic screening of mcr-1-positive 
colistin-resistant E. coli strains.  
Methods 
The Colistin-MAC test is based on colistin MIC testing, in absence or presence of DPA, in a broth 
microdilution format according to the CLSI standard [10]. Colistin sulphate (Sigma-Aldrich, St 
Louis, MO, USA) concentrations tested ranged from 0.125 to 8.0 µg/mL, alone or in combination 
with DPA at a fixed concentration of 900 µg/mL. DPA was chosen since it was reported to have 
greater selectivity for zinc ions [11], and exhibited a better performance than EDTA in phenotypic 
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assays for detection of zinc-β-lactamases [12]. The DPA (Sigma-Aldrich) stock solution was 
prepared in dimethyl sulfoxide (DMSO) (SERVA, Heidelberg, Germany) at a concentration of 100 
mg/mL and stored at -20°C. Cation-adjusted Mueller Hinton broth (MHB) (Becton Dickinson, 
Milan, Italy) was used as the medium for susceptibility testing. MHB containing DPA and DMSO 
at final concentrations of 900 µg/mL and 0.9% (v/v), respectively, was used for growth control. 
Susceptibility testing was carried out in 96-well microtiter plates (Sarstedt, Nümbrecht, Germany). 
Results were recorded after 20 hours of incubation at 35±2°C. Susceptibility to colistin was 
interpreted according to the EUCAST clinical breakpoints (≤ 2 µg/mL) [13]. All tests were carried 
out in duplicate. The two repetitions were considered concordant when a ≥8-fold reduction or a ≤2-
fold reduction of colistin MIC in the presence of DPA was observed in both replicates. In case of 
discordant results, a third replicate was carried out and the modal value was considered.  
The Colistin-MAC test was evaluated with 74 colistin-resistant strains from our Laboratory 
collection (Table S1), including: i) 61 strains carrying mcr-1-like genes, in which the genes had 
been detected by PCR or Whole-Genome Sequencing (WGS); ii) 13 strains in which the absence of 
mcr-1-like and mcr-2 genes had been confirmed by RT-PCR and end-point PCR (Table S2); in nine 
of these strains the absence of all known mcr genes mcr-1 to mcr-4 had also been confirmed by 
WGS analysis. Most strains were E. coli (N=65), and a few belonged to other enterobacterial 
species including Klebsiella pneumoniae (N=6), Citrobacter braakii (N=1), Citrobacter freundii 
complex (N=1) and Enterobacter cloacae complex (N=1). The tested strains included 70 isolates of 
clinical origin (blood or urine cultures, or surveillance rectal swabs), one isolate of environmental 
origin, and three laboratory-derived E. coli J53 transconjugants harboring different mcr-1-carrying 
plasmids (Table S1). Some of the investigated strains have been previously reported, while others 
are part of an ongoing study. All E. coli strains were confirmed to be clonally unrelated by random 
amplification of polymorphic DNA PCR (Table S1). The K. pneumoniae strain carrying mcr-1-like 
gene was ST1 and presented a capsular wzi-19 allele, while that carrying mcr-1.2 was ST512 and 
presented a capsular wzi-154 allele.   
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The effect of DPA in increasing colistin susceptibility of mcr-1-like positive strains was also tested 
in a disc-diffusion format [14], using colistin discs (10 µg, Thermo Scientific™ Oxoid™, Waltham, 
MA USA) added with either 7.5 µL or 10 µL of the DPA stock solution (i. e. 750 or 1000 µg per 
disc, respectively) before placing the disc onto the inoculated medium. 
Results 
The tested strains exhibited a colistin MIC ranging from 4 to >8 µg/mL (Table 1), and all of them 
grew well in the presence of DPA and DMSO at the concentrations used in the test.  
In presence of DPA at 900 µg/mL, all the 53 mcr-1 positive E. coli strains exhibited a reduction of 
colistin MIC of at least an 8-fold dilution (range, 8 – ≥128 fold). A similar behavior was also 
observed with the three E. coli J53 transconjugants carrying different mcr-1 plasmids, with the mcr-
1-positive Enterobacter cloacae complex strain and with the two mcr-1-positive Citrobacter strains 
(Table 1). Discordant results between the two replicates were only observed with three mcr-1 
positive E. coli strains, which resulted in 4-fold reduction of colistin MIC in one of the two 
repetitions. In these cases, a third replicate yielded a >8-fold colistin MIC reduction (Table S1) and 
the median value was considered. Colistin MIC was increased, unchanged or at most decreased by a 
two-fold dilution with the mcr-negative E. coli and K. pneumoniae strains, but also with the two 
mcr-1-like positive K. pneumoniae strains (Table 1).  
In the disc-diffusion format, no significant differences were detected in inhibition zones between 
mcr-1-positive and mcr-negative colistin-resistant strains (data not shown), probably due to the low 
and variable diffusibility of colistin from discs [15]. 
Discussion 
The Colistin-MAC test described in this work could be a simple method for screening of mcr-1-
positive strains among colistin-resistant E. coli and, possibly also of other species of 
Enterobacteriaceae. In fact, considering as a criterion for mcr-1 positivity/negativity a ≥8-fold /≤2-
fold reduction of colistin MIC in the presence of DPA, the test was able to correctly categorize all 
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the 65 colistin-resistant mcr-1-positive E. coli (including 62 clinical strains and three laboratory-
derived transconjugants), and also a few mcr-1-positive strains of other species. The lack of 
inhibitory effect observed with the mcr-1-positive K. pneumoniae could be due to a reduced 
permeability to DPA and/or to the presence of additional unknown mechanisms of colistin 
resistance in those strains. We encountered only three results falling in the intermediate range (4-
fold colistin MIC reduction by DPA), that were confirmed as positive (≥8-fold colistin MIC 
reduction) in two additional replicates. In case of an intermediate result, we suggest repeating the 
test and, if the intermediate result is confirmed, reporting the result as indeterminate.    
This study was conceived as a preliminary proof of concept evaluation of the Colistin-MAC test 
and, as such, has a number of limitations including: i) the small sample size of investigated strains; 
ii) the limited number of investigated species, with a very small number of strains of species other 
than E. coli; iii) the small number of strains with (putative) chromosomal mechanisms of resistance, 
as negative controls; iv) the lack of strains carrying mcr genes other than mcr-1. The performance 
of this test should be confirmed with a larger collection of strains representative of different species 
and different colistin resistance mechanisms. The Colistin-MAC test has also some inherent 
limitations: i) the test is apparently not working with K. pneumoniae; ii) the execution requires the 
preparation of test-specific BMD panels, which can be labor-intensive and could increase costs in 
case of commercial production. In this perspective, it could be interesting to evaluate the 
performance of the test carried out with the addition of DPA directly to wells of a commercial 
panel.  
Nevertheless, the possibility to presumptively detect E. coli strains with plasmid-mediated colistin 
resistance due to acquisition of mcr-1 genes (which overall appear to be the most prevalent strains 
with transferable colistin resistance worldwide) with a test that can be set up also in basic 
laboratories not equipped with facilities for molecular testing, could be of remarkable importance 
for surveillance purposes, especially in low-income settings.   
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Table S1. List of tested strains with mechanisms of colistin resistance, colistin MIC values in absence and 
presence of DPA, and references.       
Table S2. Oligonucleotides and probes used for the RT-PCR and end-point-PCR for detection of mcr-1-like 
and mcr-2-like genes.  
Table 1. Bacterial strains tested in this study, and colistin MIC values measured by broth microdilution in 
absence or presence of 900 mg/mL DPA (Colistin-MAC test). For a detailed description of tested strains 
and results see Table S1. 
Species Mechanism of Colistin resistancea 
No. of 
strains 
MIC 
Colistin 
(µg/mL) 
(median 
value) 
MIC Colistin 
(µg/mL) + DPA 
900 µg/ml 
(median value) 
Fold of 
MIC 
reduction 
Escherichia coli 
mcr-1/ mcr-1-like 53 4 - >8 (8) ≤0.125 - 1 (≤0.125) 8 - ≥128 
mcr-NEG, n.d. 9 4 - 8 (8) 4 - >8 (8) ≈b 
Escherichia coli 
J53AZIR 
Transconjugants 
mcr-1-like 3 4 (4) ≤0.125 - 0.5 (0.25) 8 - ≥32 
Klebsiella 
pneumoniae 
mcr-1-like/mcr-1.2 2 8 - >8 >8 ≈b 
mcr-NEG  
PmrB 
mutant/inactivated 
mgrB/n.d. 
4 >8 >8 ≈b 
Citrobacter braakii mcr-1 1 8 0.5 16  
Citrobacter freundii 
complex mcr-1 1 8 ≤0.125 ≥64 
Enterobacter cloacae 
complex mcr-1 1 >8 ≤0.125 ≥128 
a mcr-1-like indicates that the gene was amplified with primers for mcr-1 but was not entirely sequenced; 
mcr-NEG indicates that the strain was negative for mcr-1-like and mcr-2-like genes as assessed by RT-
PCR and end-point PCR. In some cases, WGS data confirmed negativity for all known mcr-genes; n.d., 
indicates that the colistin resistance mechanism remained not determined.  
b ≈ indicates that colistin MIC, in presence of DPA, was increased, unchanged or at most decreased by a 
two-fold dilution. 
 
